Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Hybridoma Technology01:31

Hybridoma Technology

16.6K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
16.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.

Nature immunology·2026
Same author

Cooperation of ILC2s and T<sub>H</sub>2 cells in the expulsion of intestinal helminth parasites.

Nature reviews. Immunology·2023
Same author

Mouse IgG2a Isotype Therapeutic Antibodies Elicit Superior Tumor Growth Control Compared with mIgG1 or mIgE.

Cancer research communications·2023
Same author

Introducing our new series: Clinical and Experimental Treatment of….

Clinical and experimental immunology·2022
Same author

Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells.

Biomolecules·2022
Same author

Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment.

Biomedicines·2022
Same journal

The many faces of cytokine storm syndrome: immunopathogenic mechanisms and clinical implications for a better patient management.

Clinical and experimental immunology·2026
Same journal

PD-1 Engagement and Circulating Th17 Effector Activity During Secukinumab Treatment in Plaque Psoriasis.

Clinical and experimental immunology·2026
Same journal

Henoch-Schoenlein purpura (HSP) like lesions in IL12RB1 and IL12B defects - A multi-centric experience from India.

Clinical and experimental immunology·2026
Same journal

Case Series on the Efficacy of Daratumumab in Treating Patients with Anti-Interferon-Gamma Autoantibodies.

Clinical and experimental immunology·2026
Same journal

Deleterious germline CARD11 gain-of-function variants alter human B-cell and CD4+ T-cell differentiation and function.

Clinical and experimental immunology·2026
Same journal

Clinical, genetic, and functional characterization of novel NFKB1 variants in Chinese patients with primary immunodeficiency.

Clinical and experimental immunology·2026
See all related articles

Related Experiment Video

Updated: Dec 1, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K

Isotype selection for antibody-based cancer therapy.

N Vukovic1, A van Elsas2, J S Verbeek3

  • 1Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Ashworth Laboratories, Edinburgh, UK.

Clinical and Experimental Immunology
|November 6, 2020
PubMed
Summary
This summary is machine-generated.

Monoclonal antibodies (mAbs) are revolutionizing cancer therapy. Optimizing antibody isotype selection and Fc engineering can improve treatment efficacy for more patients.

Keywords:
Fc tailcancereffector functionsisotypemAbs

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.4K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.0K

Related Experiment Videos

Last Updated: Dec 1, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.4K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.0K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Monoclonal antibodies (mAbs) have transformed cancer treatment by targeting tumor-specific receptors and immune modulators.
  • Fc-mediated effector functions are crucial for the anti-tumor activity of many therapeutic mAbs.
  • Different immunoglobulin (Ig) isotypes vary in their Fc receptor binding and complement activation capabilities, influencing immune responses.

Purpose of the Study:

  • To review the therapeutic effector functions of various antibody isotypes.
  • To discuss Fc-engineering strategies for enhancing mAb efficacy.
  • To highlight the importance of optimal isotype selection in antibody development.

Main Methods:

  • Review of current scientific literature on mAb effector functions.
  • Analysis of isotype-dependent immune responses.
  • Discussion of Fc-engineering approaches.

Main Results:

  • Fc-mediated functions are critical for the efficacy of numerous therapeutic mAbs.
  • The choice of antibody isotype directly impacts the type of immune response elicited.
  • Fc optimization strategies hold potential for improving mAb-based cancer therapies.

Conclusions:

  • Optimal isotype selection and Fc engineering are vital for maximizing the clinical benefit of mAbs.
  • Improving mAb design can lead to better patient outcomes in cancer treatment.
  • Further research into Fc-mediated functions can unlock new therapeutic possibilities.